Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cell cycle-dependent translation-mediated turnover of the long noncoding RNA Malat1.

Created on 25 Aug 2026

Authors

Leah M Plasek-Hegde, Yeolhoe Kim, Rahul V Gupta, Emily A Dangelmaier, Sigrid Nachtergaele, Nadya Dimitrova

Published in

The Journal of cell biology. Volume 225. Issue 10. Oct 05, 2026. Epub Aug 25, 2026.

Abstract

Increased abundance of the nuclear long noncoding RNA (lncRNA) Malat1 drives metastatic progression and is a strong predictor of poor patient prognosis. Although the mechanism that stabilizes Malat1 through processing of its 3' terminus is well-characterized, the pathways governing its turnover remain poorly understood. Here, we show that upon exit from mitosis, Malat1 localizes to the cytoplasm, where it is degraded during early G1, resetting its abundance at the start of each cell cycle. Mechanistically, we demonstrate that Malat1 turnover is mediated by a translation- and Smg1-dependent decay pathway and triggered by redundant elements. Importantly, failure to reset Malat1 levels in early G1, due to decay inhibition or in the absence of progression through mitosis, results in Malat1 accumulation. These findings uncover a cell cycle-dependent mechanism that harnesses the translation machinery to regulate Malat1 abundance and identify cancer cell dormancy as a potential mechanism underlying the widespread overexpression of Malat1 in cancer.

PMID:
42640252
Bibliographic data and abstract were imported from PubMed on 25 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement